Medical device trade shows generate a lot of conversations and relatively few opportunities. The reason is not that the conversations are bad — medtech booth discussions are often unusually substantive. It is that almost none of that substance survives into the CRM.
Why the standard lead form fails in medtech
A generic lead record captures name, company, product interest, maybe a note. In most sectors that is thin but workable. In medtech it is close to useless, because the sale turns on things the form has no field for.
The buying group is large. A single device purchase can involve a clinical champion who wants it, biomedical engineering who will maintain it, IT who must integrate it, infection control who must approve the materials, procurement who runs the process, and finance who releases the capital. Sometimes a group purchasing organisation decides which vendors are eligible before any of that starts.
The person at your booth is usually one node, and frequently not the decisive one.
The regulatory gate comes first. If your device does not have the certification the buyer's market requires — EU MDR, FDA clearance, UKCA — the clinical merits are irrelevant. This is a binary qualifier that generic lead scoring never asks about.
Capital cycles are rigid. Hospital capital budgets are annual and generally inflexible. Miss the window and the deal waits a year, regardless of enthusiasm.
The fields that actually predict a medtech close
- Device class and intended use — Class I, IIa, IIb, III changes the whole pathway
- Regulatory status required — MDR, FDA 510(k) or PMA, UKCA, market-specific
- Installed base — what they run now, its age, its end-of-support date
- Procurement route — direct, tender, framework, or GPO
- Capital budget cycle — when the window opens; whether funds are allocated
- Clinical champion — who inside actually wants this
- Sign-off chain — every function that must approve
- Integration requirements — for connected devices, the IT environment
A record carrying these can be worked by someone who was not at the booth. That is the test.
The end-of-support field is underrated
If there is one field most medtech teams do not capture and should, it is when the incumbent equipment reaches end of support.
It is a hard date, it is known to the buyer, and it creates an unavoidable decision. A hospital running equipment that loses vendor support in eighteen months must act. That is a stronger buying signal than any stated interest, and it lets you sequence follow-up around a real deadline rather than a guess.
Ask it directly. Biomedical engineering staff almost always know the answer.
Where the leads actually die
Industry research has consistently found that the large majority of trade show leads are never followed up. In medtech the mechanism is specific and worth naming.
The rep has a genuinely good twenty-minute conversation covering workflow, integration and procurement. Between visitors there is no time to write it up. By the evening, four more conversations have happened. By the end of the show, the record says "interested in the Class IIb unit — follow up."
Three weeks later someone tries to act on it, has nothing to say beyond a generic email, and the clinician does not reply — because the message demonstrates that nobody listened.
The lead was not lost through neglect. It was lost through compression. There was never a moment in which to record what was said.
Fixing the compression problem
Three approaches, in ascending order of reliability:
1. Structured forms filled during the conversation. Better than memory, but the rep is typing instead of listening, and medtech clinicians notice.
2. Voice notes after each conversation. Better still — captures more detail. But it requires a gap between visitors that busy medtech booths do not have, and the notes still need transcribing.
3. Capturing the conversation itself. The rep talks normally, and the structured fields are extracted afterwards. No typing, no gap required, no reliance on recall.
This is the approach Confee takes: the booth conversation becomes name, company, requirement, timeline and next step in the CRM before the next visitor arrives.
The recording question in medtech
Recording rules follow the venue's jurisdiction, not the sector — MEDICA in Düsseldorf means German §201 StGB and all-party consent; RSNA in Chicago means Illinois all-party consent.
Medtech adds one sector-specific caution: clinicians explain requirements through examples, and sometimes those examples are real patients. If a conversation moves to a specific identifiable case, you may be touching protected health information.
Brief booth staff to:
- Steer requirement discussions toward categories, volumes and workflows
- Stop recording if a specific patient is described
- Never retain anything patient-identifying
The medtech capture checklist
Before the show
- Sector-specific CRM fields created — not generic lead fields
- Reps briefed on the regulatory qualifier and the end-of-support question
- Consent script prepared for the venue's jurisdiction
- HIPAA / patient-data boundary briefed
Per conversation
- Regulatory requirement established early — it is a binary qualifier
- Installed base and end-of-support date captured
- Sign-off chain identified
- Capital window confirmed
- Next step agreed out loud
After
- Follow up referencing the clinical specifics, not the product
- Sequence by capital window, not by enthusiasm
The short version
Medtech leads fail because the record is too thin to work, not because the conversation was bad. Capture the regulatory gate, the installed base and its end-of-support date, the capital window and the sign-off chain — and capture them during the conversation, because there is no time afterwards.
Related reading:
- MEDICA Lead Capture — the largest medical fair in the world
- RSNA Lead Capture — radiology and imaging capital sales
- Event Lead Scoring — building the qualification model
FAQ
Why do medtech trade show leads convert so poorly?
Because the record rarely contains what the sale turns on. Purchases involve a clinical champion, biomedical engineering, IT, procurement and often a GPO, constrained by an annual capital cycle. A name and a product interest cannot be worked.
What should a medtech lead record contain?
Device class and intended use, regulatory status for the buyer's market, installed base and its end-of-support date, procurement route including tenders and GPOs, capital budget timing, clinical champion, and the full sign-off chain.
How does the capital budget cycle affect medtech follow-up?
Decisively. Hospital capital budgets are annual and inflexible, so missing the window means waiting a year. Capturing when the window opens is often more predictive of a close than stated interest.
Do recording rules differ for medtech events?
Recording rules follow the venue's jurisdiction, not the sector. But medtech adds a caution: if a clinician describes a real patient case, you may be touching protected health information. Steer toward categories and volumes, and stop recording if a specific patient is described.